| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
1.53(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.23 - $9.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
585,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,011,778 |
| Total People Bought |
0 |
0 |
0 |
7 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
775,593 |
1,206,168 |
1,357,304 |
2,009,275 |
| Total Sell Value |
$6,587,745 |
$9,420,070 |
$9,994,774 |
$10,729,161 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
18 |
37 |
60 |
105 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Raab Michael |
President & CEO |
• • – |
2020-06-10 |
4 |
A |
$0.00 |
$0 |
I/I |
1,235 |
47,492 |
|
- |
|
| New Enterprise Associates 12, Limited Partnership |
10% Owner |
– – • |
2020-06-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,482,809) |
8,086,401 |
|
- |
|
| Mott David M |
Director |
– • – |
2020-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,079 |
101,640 |
|
- |
|
| Jacobs Jeffrey W |
Chief Scientific OfficerOffice |
• – – |
2020-06-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
145,566 |
|
-28% |
|
| Blanks Robert |
See RemarksOfficer |
• – – |
2020-06-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
115,395 |
|
-28% |
|
| Lundberg Jan M |
Director |
– • – |
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,497 |
35,618 |
|
- |
|
| Rodgers Richard J |
Director |
– • – |
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
9,233 |
77,610 |
|
- |
|
| Mott David M |
Director |
– • – |
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
12,995 |
100,561 |
|
- |
|
| Bertrand William C Jr |
Director |
– • – |
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
7,523 |
59,658 |
|
- |
|
| Cadoret-Manier Onaiza |
Director |
– • – |
2020-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,155 |
6,155 |
|
- |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2020-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
13,000 |
|
- |
|
| Renz Justin A |
Chief Financial OfficerOfficer |
• – – |
2020-06-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,000 |
|
-25% |
|
| Raab Michael |
President & CEO |
• • – |
2020-06-01 |
4 |
AS |
$7.33 |
$169,635 |
I/I |
(23,128) |
46,257 |
|
-24% |
|
| Rodriguez Susan |
Chief Commercial Officer |
• – – |
2020-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2020-05-11 |
4 |
GA |
$0.00 |
$0 |
I/I |
500 |
2,566 |
|
- |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2020-05-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,500 |
100,108 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2020-05-05 |
4 |
AS |
$7.03 |
$31,536 |
I/I |
(4,486) |
69,385 |
|
-13% |
|
| Raab Michael |
President & CEO |
• • – |
2020-05-04 |
4 |
AS |
$7.01 |
$111,686 |
I/I |
(15,941) |
73,871 |
|
-10% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2020-04-27 |
4 |
AS |
$7.44 |
$133,173 |
D/D |
(17,824) |
101,608 |
|
-23% |
|
| Raab Michael |
President & CEO |
• • – |
2020-04-17 |
4 |
AS |
$7.02 |
$66,169 |
I/I |
(9,428) |
89,812 |
|
-21% |
|
| Raab Michael |
President & CEO |
• • – |
2020-04-16 |
4 |
AS |
$7.01 |
$73,642 |
I/I |
(10,500) |
99,240 |
|
-14% |
|
| Raab Michael |
President & CEO |
• • – |
2020-04-15 |
4 |
AS |
$7.03 |
$3,515 |
I/I |
(500) |
109,740 |
|
-15% |
|
| Raab Michael |
President & CEO |
• • – |
2020-03-02 |
4 |
AS |
$7.01 |
$143,284 |
I/I |
(20,428) |
110,240 |
|
-11% |
|
| Raab Michael |
President & CEO |
• • – |
2020-03-02 |
4 |
AS |
$7.00 |
$77,861 |
D/D |
(11,123) |
208,057 |
|
-11% |
|
| Raab Michael |
President & CEO |
• • – |
2020-03-02 |
4 |
OE |
$1.08 |
$12,013 |
D/D |
11,123 |
219,180 |
|
- |
|
538 Records found
|
|
Page 11 of 22 |
|
|
0.29 (4.2%) 
